Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence
Open Access
- 1 January 2010
- journal article
- review article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. 4, 1-9
Abstract
Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence Francesco PattiDepartment of Neurology, University of Catania, Catania, Italy Poor treatment adherence is problematic in many therapy areas, including multiple sclerosis (MS). Several immunomodulatory drugs are available for the treatment of MS, all of which require frequent parenteral administration. Current first-line therapies are two formulations of interferon (IFN) beta-1a, one of IFN beta-1b, and one of glatiramer acetate. Discontinuation of treatment is common, particularly in the first few months after initiation. Although the true effect of poor adherence to MS therapy is not known, it is likely to lead to a fall in treatment efficacy. Many factors influence a patient’s adherence to treatment, including the patient’s MS subtype and disability level, cognitive impairment resulting from MS, perceived lack of efficacy of the prescribed medication, and adverse events associated with MS therapy. This article summarizes the barriers to adherence to MS therapies, and discusses patient management strategies that can be employed to encourage adherence. Future advances in the field of MS treatment will be explored, including the development of orally administered drugs, which may enhance adherence.Keywords: multiple sclerosis, adherence, compliance, interruption, adverse events, efficacy, tolerability, managementKeywords
This publication has 48 references indexed in Scilit:
- Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week resultsMultiple Sclerosis Journal, 2008
- Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosisMultiple Sclerosis Journal, 2007
- Disruption of the interaction of T cells with antigen‐presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formationArthritis & Rheumatism, 2005
- A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of avonex in patients with multiple sclerosisClinical Therapeutics, 2004
- Adherence, Quality of Life, and General Satisfaction with Co-formulated Zidovudine, Lamivudine, and Abacavir on Antiretroviral-Experienced PatientsHIV Research & Clinical Practice, 2004
- Long-Term Treatment Optimization in Individuals with Multiple Sclerosis Using Disease-Modifying TherapiesJournal of Neuroscience Nursing, 2004
- Managing the Adverse Effects of Interferon-?? Therapy in Multiple SclerosisDrug Safety, 2000
- Improving the Convenience of Home-Based Interferon beta-la Therapy for Multiple SclerosisJournal of Neuroscience Nursing, 1999
- Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosisMultiple Sclerosis Journal, 1999
- Cognitive dysfunction in multiple sclerosis.Neurology, 1991